Trials / Completed
CompletedNCT04577651
Cartesia eXTend 3D Study
Study to Evaluate Boston Scientific Vercise Cartesia 16-contact Directional Lead (X/HX) With Deep Brain Stimulation (DBS) Systems for the Treatment of Parkinson's Disease (PD)
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 58 (actual)
- Sponsor
- Boston Scientific Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to document patient outcomes including effectiveness for Boston Scientific Corporation's Vercise Cartesia 16-contact Directional Lead(s) (X/HX) with Deep Brain Stimulation (DBS) systems for the treatment of Parkinson's Disease (PD).
Detailed description
Subjects will receive Deep Brain Stimulation with a 16-contact Directional Lead to treat their Parkinson's Disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | 16-contact Directional Deep Brain Stimulation | Deep Brain Stimulation with 16-contact Directional Lead |
Timeline
- Start date
- 2020-11-02
- Primary completion
- 2023-02-27
- Completion
- 2025-01-28
- First posted
- 2020-10-08
- Last updated
- 2025-02-21
- Results posted
- 2024-03-29
Locations
10 sites across 3 countries: Germany, Netherlands, United Kingdom
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT04577651. Inclusion in this directory is not an endorsement.